Is whole body low dose CT still necessary in the era of <sup>18</sup>F-FDG PET/CT for the assessment of bone disease in multiple myeloma patients?
Nicola Maggialetti(University of Molise), Giuseppe Rubini(University of Bari Aldo Moro), Luca Brunese, Carla Minoia(Istituto Tumori Bari), Attilio Guarini(Istituto Tumori Bari), Cristina Ferrari(University of Bari Aldo Moro), Anna Nappi, Angela Maria Quinto(Platinum Group Coatings (United States)), Bernardo Rossini(Istituto Tumori Bari), Marcello Zappia(University of Molise)
Cited by 4
Related Papers
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation
|Clinical and Translational Imaging|2021|171
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations
|Blood Reviews|2016|141
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
|The Lancet Haematology|2018|116